$AVR DurAVR 1-year preview
Technical success rose 43/50→50/50 as the valve and delivery system evolved. Mean STS 4.7%, 61% NYHA III/IV, 9 type 1 bicuspids.
2 disabling strokes by day 30 in 100. One later in the prior 65. Watching gradients, EOA and new strokes/CV admissions.
3
9
820
$AVR Paradigm Powered Secondary Review
10) Moderate/severe PPM vs Evolut- Noninferiority
My base case is ~3% moderate/severe PPM for DurAVR vs ~8% for Evolut at 1 year, supporting noninferiority with a potential numerical advantage. Cross-study model assuming 47% small/53% med.
6
473
$AVR Paradigm Powered Secondary Review
9) Effective orifice area vs Evolut- Superiority
My conservative base case is ~0.05–0.10 cm² larger EOA with DurAVR at 1 year. Modeled using comparable CT annulus-area bands, assuming 47% small/53% medium and no large valves.
1
9
660
I learned I have ADHD today 😂
BREAKING: Cognitive researchers confirm that leaving half-drunk mugs of coffee, water glasses, and soda cans scattered across every room in the house isn't "sloppiness"—it is a documented visual processing quirk called "Salience Habituation."
If you live with someone who leaves a trail of 6 abandoned drinks behind them every day, here is what is actually happening inside their brain: 1/5
60
$AVR Paradigm Powered Secondary Review
8) LV mass index regression vs Sapien- Superiority
The most difficult to model. DurAVR showed rapid LV mass regression (~18%) at 6 months—broadly comparable in magnitude to older-generation SAPIEN results at 1 year.
1
6
434
$AVR Paradigm Powered Secondary Review
7) Indexed aortic flow reversal ratio vs Sapien- Superiority
My base case favors DurAVR, with indexed flow reversal ~2.5–2.6 %/cm² at 1 year if its 6-month performance holds. Early paired MRI data showed ~33% improvement from baseline.
1
5
439
REBOOT-PARADOX. No significant survival difference does not establish no benefit.
Among survivors, symptom improvement and HF rehospitalization favored immediate TAVR.
For $AVR, the question is whether DurAVR’s physiologic flow translates into better outcomes.
Does early TAVR improve survival in symptomatic paradoxical low-flow, low-gradient aortic stenosis?
REBOOT-PARADOX (n=120): death 29% vs 37% on medical therapy (P=.60). Symptoms and readmissions favored TAVR; trial stopped early.
@JuMehilli
New in #JACC: bit.ly/4zMzVK3
1
5
673
LFLG aortic stenosis are among the sickest patients. Notice the heart remodels over several years leading to improved outcomes.
$AVR has shown rapid LV mass regression following durAVR placement in EFS; Garg P, et al Eur Heart J Valv Struct Heart Dis. 2026;2(1).
Flow matters.
1
3
244
$AVR Paradigm Powered Secondary Review
6) Mean aortic valve gradient in patients under 75 vs Sapien- Superiority
My base case for DurAVR’s mean gradient at 1 year in patients under 75 comes in ~2 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
2
8
735
$AVR
Key Market Takeaways
•Market Size, 2025: US$ 8.41 billion
•Projected Market Size, 2034: US$ 30.01 billion
•CAGR, 2026–2034: 15.2%
•High-Growth Region: Asia Pacific
•Addressable Market: US$ 164.02 billion
finance.yahoo.com/healthcare…
.@EdwardsLifesci CEO says ‘more competition is coming’ in #TAVR | #structuralheart massdevice.com/edwards-lifes…
$AVR Paradigm Powered Secondary Review
4) Mean aortic valve gradient in small annuli vs Sapien- Superiority
My base case for DurAVR’s mean gradient at 1 year in annuli <430 mm² comes in ~2.5 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
1
9
663




